#USA #New York #AI Technology #Inductive Bio #ADMET

Inductive Bio's Groundbreaking Achievement in ADMET Prediction

In an impressive display of innovation and scientific prowess, Inductive Bio has claimed victory in the OpenADMET-ExpansionRx blind challenge. This competition, recognized as the largest in the field, attracted over 370 submissions from a wide range of competitors, including prominent figures from pharmaceutical and biotech companies, as well as academia and AI organizations. Inductive Bio's cutting-edge Beacon models triumphed, marking the company's second consecutive win following its success in the Polaris ADMET challenge in 2025.

The OpenADMET-ExpansionRx challenge was designed to push the boundaries of drug discovery, particularly in the context of real-world applications. Participants were tasked with predicting nine essential ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) endpoints from a drug discovery campaign aimed at addressing conditions like myotonic dystrophy, ALS, and dementia.

This unique and competitive format, where participants tackled the properties of completely unseen compounds from active drug programs, represents a pivotal opportunity for the industry to gauge the current state of ADMET modeling against the backdrop of genuine drug discovery scenarios. The challenge's design underscores the necessity of efficient and reliable predictive models in developing safer and effective therapeutics.

Josh Haimson, the co-founder and CEO of Inductive Bio, expressed pride in the team's achievement, stating, "We are thrilled to have placed first among such esteemed competitors, reinforcing the standing of our Beacon models in ADMET predictions. This success further validates our team's experience and dedication to building a diverse and high-quality dataset. It illustrates that our technology can adeptly guide programs toward development candidates, even within challenging and novel chemical spaces."

A notable aspect of Inductive's Beacon models is their training on one of the industry's most extensive and varied ADMET datasets, strategically enhanced by proprietary fine-tuning technology. This allows the models to adapt global trends to new chemical contexts effectively. By doing so, they lead small molecule discovery efforts toward compounds with improved dosages, safety margins, and greater viability earlier in the discovery phase.

The significance of this achievement further extends beyond competition accolades. Inductive Bio has established itself as a driving force in the biopharmaceutical sector, currently powering the discovery programs of an array of biopharmaceutical firms. The company has demonstrated its capacity to deliver multiple development candidates in significantly shorter timelines than the industry requires.

Additionally, this recent triumph in the OpenADMET challenge comes on the heels of another noteworthy announcement: Inductive Bio has secured up to $21 million in funding from ARPA-H. This grant is intended to support a multi-institutional initiative focused on developing next-generation drug toxicity models, ultimately enhancing the safety of therapeutics while minimizing reliance on animal testing—a growing concern within the pharmaceutical industry.

Inductive Bio operates by constructing virtual chemistry labs that empower researchers in the field to design higher-quality molecules, at a faster pace. These virtual labs harness proven scientific best practices across various domains—medicinal chemistry, computational chemistry, DMPK, and safety—to facilitate consistent, high-quality decision-making during the discovery process. Within these platforms, AI chemistry assistants collaborate with predictive ADMET and PK models, as well as human-relevant digital organ technologies, enabling scientists to evaluate numerous hypotheses in silico while identifying key risks sooner.

The integration of advanced technology alongside traditional chemistry practices ultimately accelerates the process of advancing the most promising molecules from virtual settings to practical laboratory experiments.

As Inductive Bio continues its trajectory of success, it not only showcases the potential of AI in drug discovery but also contributes to redefining how the industry approaches therapeutic development. This latest victory is a testament to the relentless innovation and commitment to excellence that defines Inductive Bio's mission to enhance drug discovery processes and bring safer therapeutics to market.

For those interested in exploring more about Inductive Bio and its pioneering work, further information is available at Inductive Bio's Website.